Research

Hormonal

GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity by mimicking endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite via central nervous system signaling.

GLP-1 medications are highly effective for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to boost insulin when needed, lower blood sugar, slow digestion, and reduce hunger. While they often require injections, many are now available as once-weekly shots or even pills. Side effects like nausea are common at first but usually fade. They are not for type 1 diabetes. Always combine with diet and exercise.

StrongSupportsVERY_HIGH confidence
GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression.
Zhikai Zheng et al. · Signal Transduction and Targeted Therapy · 2024

Why this rating

The paper cites multiple FDA approvals, large-scale clinical trials (Phase II/III), and extensive historical data.

Source

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Zhikai Zheng et al. · Signal Transduction and Targeted Therapy · 2024

DOI 10.1038/s41392-024-01931-z

narrative_reviewCited 768×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →